SNGXSOLIGENIX, INC.

Nasdaq www.soligenix.com


$ 3.95 $ -0.09 (-2.17 %)    

Friday, 14-Jun-2024 15:48:58 EDT
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 4.06
$ 4.06
$ 0.00 x 0
$ 0.00 x 0
$ 3.95 - $ 4.61
$ 3.30 - $ 32.00
472,171
na
2.67M
$ 0.70
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-15-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-21-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-29-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-18-2021 03-31-2021 10-Q
14 03-30-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 05-15-2020 03-31-2020 10-Q
18 03-30-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 03-26-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-11-2018 03-31-2018 10-Q
26 03-15-2018 12-31-2017 10-K
27 11-06-2017 09-30-2017 10-Q
28 08-11-2017 06-30-2017 10-Q
29 05-11-2017 03-31-2017 10-Q
30 03-27-2017 12-31-2016 10-K
31 11-10-2016 09-30-2016 10-Q
32 08-11-2016 06-30-2016 10-Q
33 05-12-2016 03-31-2016 10-Q
34 03-24-2016 12-31-2015 10-K
35 11-12-2015 09-30-2015 10-Q
36 08-12-2015 06-30-2015 10-Q
37 05-14-2015 03-31-2015 10-Q
38 03-25-2015 12-31-2014 10-K
39 11-10-2014 09-30-2014 10-Q
40 08-11-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 watching-soligenix-zacks-small-cap-research-gives-stock-32-price-valuation-says-model-is-highly-dependent-upon-continued-clinical-success-of-the-companys-pipeline-and-will-be-adjusted-accordingly-based-upon-future-clinical-results

https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_06142024_SNGX_Bautz.pdf

 soligenix-has-filed-a-new-patent-application-titled-compositions-and-methods-of-manufacturing-trivalent-filovirus-vaccines

https://ppubs.uspto.gov/pubwebapp/external.html?q=(20240189413).pn

 soligenix-intends-to-effect-reverse-stock-split-of-common-stock-at-ratio-of-1-post-split-share-for-every-16-pre-split-shares

Soligenix's common stock will continue to be traded on The Nasdaq Capital Market under the symbol SNGX and will begin tradi...

 soligenix-receives-notice-of-allowance-for-us-patent-titled-thermostable-vaccine-compositions-and-methods-of-preparing-same

https://patentcenter.uspto.gov/applications/17316585/ifw/docs

 soligenix-regains-compliance-with-nasdaq-stock-markets-requirement-that-co-have-shareholders-equity-of-at-least-25m

- SEC Filing

 soligenixs-clinical-results-from-hybryte-compatibility-study-for-cutaneous-t-cell-lymphoma-published-in-jeadv-clinical-practice

The treatment response results of 22% following 8 weeks of twice weekly HyBryte therapy reinforces and confirms the results of ...

 soligenix-extends-patent-protection-for-its-filovirus-vaccine-platform-to-uk-and-south-africa

Includes thermostabilized Ebola vaccines MarVax and SuVax Includes nanoemulsion adjuvant compatible with lyophilization

 why-alcoa-shares-are-trading-higher-here-are-20-stocks-moving-premarket

Shares of Alcoa Corporation (NYSE: AA) rose sharply in today’s pre-market trading after the company reported better-than-expec...

 sp-500-down-over-1-us-retail-sales-increase-07-in-march

U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0...

 why-ultragenyx-pharmaceutical-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...